ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Legato Capital Management LLC

Legato Capital Management LLC lowered its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 45.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,370 shares of the specialty pharmaceutical company’s stock after selling 6,910 shares during the period. Legato Capital Management LLC’s holdings in ANI Pharmaceuticals were worth $661,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals in the first quarter valued at approximately $28,000. Hantz Financial Services Inc. increased its holdings in shares of ANI Pharmaceuticals by 202.6% in the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 237 shares during the period. State of Wyoming acquired a new position in shares of ANI Pharmaceuticals in the second quarter valued at approximately $50,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of ANI Pharmaceuticals by 30.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock valued at $86,000 after purchasing an additional 253 shares during the period. Finally, Federated Hermes Inc. acquired a new position in shares of ANI Pharmaceuticals in the third quarter valued at approximately $93,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

ANIP has been the topic of a number of recent research reports. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Thomas Andrew Rowland sold 459 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $79.21, for a total transaction of $36,357.39. Following the sale, the senior vice president directly owned 38,271 shares in the company, valued at approximately $3,031,445.91. The trade was a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Patrick D. Walsh sold 10,000 shares of the business’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total value of $806,300.00. Following the completion of the transaction, the director directly owned 38,432 shares of the company’s stock, valued at approximately $3,098,772.16. This trade represents a 20.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 91,427 shares of company stock valued at $7,089,066 in the last 90 days. 8.10% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Stock Down 1.6%

ANI Pharmaceuticals stock opened at $81.41 on Wednesday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. ANI Pharmaceuticals, Inc. has a 1-year low of $57.33 and a 1-year high of $99.50. The company has a market cap of $1.85 billion, a PE ratio of 20.61 and a beta of 0.46. The stock’s 50 day moving average price is $78.32 and its 200 day moving average price is $79.85.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The firm had revenue of $237.46 million for the quarter, compared to the consensus estimate of $207.63 million. During the same period in the previous year, the business earned $1.70 earnings per share. The company’s revenue for the quarter was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.